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Hepatitis C virus (HCV) infection has become a leading killer worldwide, 
affecting more than 170 million people and leading to cirrhosis of the liver, end-stage 
liver disease, and hepatocellular carcinoma. Current therapies for HCV are associated 
with significant side effects, as well as increased resistance. Therefore, there is a clear 
need for a less toxic and more effective therapy. RNA is becoming an important 
therapeutic target, despite the challenge associated with developing molecules targeting 
RNA. The HCV internal ribosome entry site (IRES) located at the 5’ untranslated region 
of the viral RNA has become a most attractive therapeutic target. Domain II of the HCV 
IRES has a 90o bent helical structure, which is crucial for the function of the IRES. 
Benzimidazole based HCV replication inhibitors that exert their activity by altering the 
structure of the domain IIa of the HCV IRES have been reported.     
 The Rainier group, in collaboration with the Davis, Cheatham and Hagedorn 
groups of the University of Utah, plan to reach the goal of developing efficient HCV 
therapeutics. The plan centers around utilizing the previously reported synthesis of 
quaternary substituted indolines and thiopyranylindolines by Rh(II) mediated diazo 
decomposition to examine the scope of potential HCV inhibitors. A serotonin derivative 
was coupled with a vinyl diazo ester in the presence of Rh2(OAc)4 to provide  a 
quaternary substituted indoline, which after cyclization with TFA provided the 
pyrroloindoline based potential HCV inhibitors.   
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Chaetomin was isolated from Chaetomium sp. and was found to possess antibiotic 
effects, immunomodulatory activity, and anti cancer activity. Thus, the fascinating 
architecture, as well as its striking biological activity, have made chaetomin an attractive 
synthetic target. The indole-diketopiperazine bridge in chaetomin is an important 
structural feature of its northern hemisphere. The bridgehead carbanion in the 
epidithiodiketopiperazine moiety was quenched with a skatole derivative to produce an 
indole-diketopiperazine coupled product.       
 Outlined here are the studies directed toward the synthesis of pyrroloindoline 
based potential HCV inhibitors, and the synthesis of the indole-diketopiperazine bridge in 




























To the most wonderful people in my life, 
my parents, sister and Aravinda, 






























ABSTRACT..................................................................................................................     iii  
LIST OF ABBREVIATIONS ......................................................................................    vii 
ACKNOWLEDGMENTS ............................................................................................      x 
CHAPTER 
1. SYNTHESIS OF HEPATITIS C VIRUS RNA TARGETED           
 THERAPEAUTICS   
 Introduction……………………………………………..........................................       1
 Results and Discussion…………………………………………………………….     13
 Conclusion…………………………………………………………………………     34
 Experimental Section……………………………………………………………....    35
 References………………………………………………………………………….    49 
  
2. STUDIES TOWARDS THE EPIDITHIODIKETOPIPERAZINE 
 ALKYLATION IN CHAETOMIN  
 Introduction……………………………………………............................................   51
 Results and Discussion……………………………………………………………...  59
 Conclusion………………………………………………………………………….   61
 Experimental Section……………………………………………………………….   62
 References…………………………………………………………………………..   64 











LIST OF ABBREVIATIONS 
 
ABSA                           4-acetamidobenzenesulfonyl azide  
Ac          acetyl 
Boc     t-Butoxycarbonyl 
Bu                                  butyl 
Bz2O2   benzoyl peroxide 
oC   celsius degrees 
calc’d   calculated 
CSA   camphorsulfonic acid 
d   doublet (spectral) 
d. r.   diastereomeric ratio 
DCM                              dichloromethane 
dd    doublet of doublet (spectral) 
ddd    doublet of doublet of doublet (spectral) 
DEAD   diethyl azodicarboxylate 
DIAD   diisopropyl azodicarboxylate 
DIPEA                           diisopropylethylamine 
DKP                               2,5-diketopiperazines  
DMA   N, N-dimethylacetamide 
DMAP              4-dimethylaminopyridine 
DMF  dimethylformamide 
dt    doublet of triplet (spectral) 
DTAD   di-t-butyl azodicarboxylate
	  viii	  
DTNB   Ellman's reagent (5,5'-dithiobis-(2-nitrobenzoic acid)) 
Et                                   ethyl 
Et2O                               diethyl ether 
EtOAc                            ethyl acetate 
ETP                                epipolythiodioxopiperazines 
FT-IR    fourier transform infrared 
g    gram(s) 
h     hour(s) 
HCV                              hepatitis C virus 
HIF-1α     hypoxia inducible factor-1 α  
HIV                               human immunodeficiency virus 
HPLC                            high pressure liquid chromatography 
iBu    iso-butyl 
IRES      internal ribosome entry site 
LAH   lithium aluminum hydride 
LHMDS   lithium hexamethyldisilazide 
LRMS (ESI)  low resolution mass spectroscopy (electrospray ionization) 
m     multiplet (spectral) 
m-CPBA                        meta-chloroperbenzoic acid 
Me                                  methyl 
MeOH                            methanol 
min                                 minute(s) 
ml     mililitre 
mol     mole(s) 
MsCl     methanesulfonyl chloride 
NBS     N-bromosuccinimide 
NMR  nuclear magnetic resonance 
	   	   	    	  
ix	  
Ns   p-nitrobenzenesulfonyl 
ppm    parts per million 
PTLC   preparative thin layer chromatography 
q    quartet (spectral) 
quant.   quantitative yield 
Rf    retention factor (chromatography) 
RNA    ribonucleic acid 
RT     room temperature 
s   singlet (spectral) 
t                                     triplet (spectral) 
TBAF    tetra-n-butylammonium fluoride 
TBAI     tetra-n-butylammonium iodide 
TBDMS (TBS)    t-butyldimethylsilyl 
TBSP         tetrakis{1-[(4-tert-butylphenyl)sulfonyl]-(2S-pyrrolidinecarboxylate}) 
tBu    tert-butyl 
td                                   triplet of doublet (spectral) 
TFA    trifluoroacetic  acid 
THF     tetrahydrofuran 
TLC     thin layer chromatography 
TMSI    trimethylsilyl iodide 
TMSOTf  trimethylsilyl trifluoromethanesulfonate 
TPP    meso-tetraphenylporphyrin 
Ts    p-toluene sulfonyl 
UTR    untranslated region 
UV    ultraviolet spectroscopy 
 
 







 I’m indebted to my research advisor Prof. Jon D. Rainier for his guidance and 
inspiration I gained from his great enthusiasm for chemistry.    
 I would like to acknowledge my committee member Prof. Gary E. Keck for his 
kind support and great teaching. Also, I would like to express my sincere gratitude to 
Prof. Peter F. Flynn for his generous support, advice and availability.   
 I’m especially grateful to the members of the Rainier group, Dr. Karthik Iyer, Dr. 
Clement Osei Akoto, Dr.Vyacheslav Boyarskikh, Dr. Jie Zhou, Dr. John Rohanna, Yuan 
Zhang, Vinson Espejo, Jin Wang, Xibo Li, Shane Smith, Dr. Jing Liu and Dr. Xin Hao, 
for their many forms of friendly assistance.       
 I would like to acknowledge our collaborator groups for the HCV project, Prof. D. 
Davis, Prof. T. Cheatham and Prof. C. Hagedorn, for their kind assistance.  
 I’m grateful to Prof. Janis Louie, Prof. Ryan Looper, Prof. Henry White, Prof. 
Michael Morse and Prof. Laya Kesner for their kindly assistance. In addition, I’m 
indebted to the Department of Chemistry for providing financial assistance in the form of 
a teaching assistantship from 2007-2008. Furthermore, I’m thankful to Jo Hoovey, 
Debbie Olson and Tomissa Nielson for their generous assistance. Also I would like to 
thank group members of Keck group, Louis group, Looper group and Sigman group for 
their friendly support.  Also I’m thankful to Dr. James Muller for mass spectral data and 
Dr. Atta Aarif for help in NMR issues. 
	  ix	  
 Especially I’m indebted to my parents, sister and Aravinda for all their 



























SYNTHESIS OF HEPATITIS C VIRUS RNA TARGETED  
THERAPEUTICS 
 
                                                             Introduction    
 Hepatitis C virus (HCV) infection has become a highly demanding global 
healthcare burden, with the likelihood of increase in the near future. More than 170 
million people (approximately 3% of the world’s population) are infected with HCV. In 
addition, approximately 3–4 million new cases of HCV infection are discovered each 
year.1 Unfortunately, most infections become chronic; a condition that is incurable in 
many patients, leading to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. 
In developed countries, HCV infection is responsible for 50–76% of all cases of liver 
cancer and for two-thirds of all liver transplants. Since the acute infection is usually 
asymptomatic, early diagnosis has become difficult, which has increased the tendency 
towards chronicity. Consequently, HCV infection has become a leading killer worldwide 
and the most common cause of liver failure in United States.2                        
 A common feature of HCV, hepatitis B, and human immunodeficiency (HIV) 
viruses is that they are primarily transmitted percutaneously. Before the screening of 
blood for HCV, HCV is mostly spread by blood transfusions, blood related products, 
haemodialysis, and organ transplantations. Nowadays HCV is mainly spread by 
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injecting drug users, and to a much lesser extent, via sexual and perinatal transmission.1 
HCV has become a significant problem in correctional facilities, where 20–40% of 
inmates are infected.2 In fact, a significant amount of patients infected with HIV are co-
infected with HCV, which increases the risk of cirrhosis.     
 The hepatitis C virus is a noncytopathic, hepatotropic member of the Flaviviridae 
family, whose primary target organ and cell are the liver and the hepatocyte respectively. 
HCV triggers a strong innate intracellular immune response in host cells as it spreads, but 
resists the function of the antiviral target genes that it induces. This immune response is 
similar in animals that overcome the infection as well as those that become persistently 
infected, implying that any influence on the outcome is indirect or obscure. However, 
viral strategies to circumvent the innate intracellular immune response, suggests its 
importance in controlling HCV infection. In addition, the outcome of HCV infection is 
mainly determined by the magnitude, diversity, and quality of the adaptive immune 
response.2             
 The outcome of HCV infection is also determined by several viral factors, such as 
HCV genotypes, replication and mutation rates. Six distinct genotypes of HCV have been 
identified that show marked differences in geographic distribution, disease progression, 
and response to therapy. Genotype I is the most prevalent viral strain in Europe and North 
America. The mutation rate, as well as the replication rate of HCV is high, which results 
in an explosive expansion of the numerous viral populations after inoculation.2   
 The HCV genome was first cloned by Houghton and colleagues in 1989. It is a 
9.6-kilobase uncapped linear single-stranded RNA molecule with positive polarity. The 
5’and 3’ end of HCV RNA contain untranslated regions (UTRs), which include control 
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elements required for translation and replication. HCV RNA genome is translated into a 
polyprotein of approximately 3,000 amino acids, comprising of four structural (C, E1, E2 
and p7) and six non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) 
(Figure 1.1).1,2             
 In developing drugs targeting HCV, researchers have focused on inhibiting 
different steps in the life cycle of the virus, which is entirely cytoplasmic. These small-
molecule, orally bio-available drugs function as inhibitors of the HCV enzymes, viral 
RNA, as well as in modulating the host immune response. Among all HCV enzymes, the 
NS3-4A serine protease and the NS5B RNA polymerase have emerged as the most 
popular therapeutic targets.3          
 HCV infects only humans and chimpanzees. Thus, research on HCV was 
hampered by the lack of small animal models, as well as lack of a robust cell-culture 
system until 2005. This new robust HCV infection system is based on a unique HCV 
genome (JFH1) derived from the blood of a Japanese patient with fulminant hepatitis, and 
shows extraordinary replication in vitro.2,4         
 The standard treatment for chronic HCV infection involves a combination of 
pegylated IFN (interferon) and ribavirin, which is also given for patients co-infected with 
HCV and HIV. It has been observed that there is a delayed response in the co-infected 
patients, which could be due to the higher viral load and lower immunity in co-infected 
patients. It is implied that the activity of this therapy is due to its anti viral effect as well 
as immunostimulatory effect. However, the therapy is associated with significant side 
effects in some patients, as well as increased resistance.1,4 Therefore, there is a clear need 
for a less toxic and more effective therapy. 
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Figure 1.1. Genomic organization of proteins of HCV 
  
 The major roadblock in HCV treatment is the rapid emergence of drug-resistant 
viruses under the selective pressures exerted by antiviral drugs. Usually in each new 
HCV genome, there is an average of one nucleotide change per replication cycle. 
Therefore, HCV exists as a genetically heterogeneous viral population, known as a 
“quasispecies,” even in untreated individuals. Thus, a successful drug candidate should 
have the ability to be effective on all HCV genotypes, as well as suppress mutations. As 
in the case of HIV, a combination of multiple drugs, directed at both viral and host 
targets, would be more promising.3 Due to the tremendous effort of researchers, an 
effective therapy for HCV may be within reach.       
            
                         Background          
 RNA is becoming an important therapeutic target due to our increasing 
knowledge of the vast role played by RNA in biochemical processes and disease 
progression.5 For instance, Erythromycin, an antibiotic in clinical practice, binds 
ribosomal RNA; also, RNA is the genetic material of the HIV and hepatitis C virus. 
Aminoglycoside antibiotics are the initial RNA targeted therapeutic, but these lack 
selectivity. Therefore, it’s worth searching for small molecules that bind to RNA targets 
more efficiently and selectively. However, developing molecules targeting RNA has 
become extremely challenging due to the lack of understanding of RNA recognition 
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principles.5 In addition, due to the heterogenous nature of RNA, it’s difficult to crystallize 
and characterize.6 Furthermore, our understanding of drug RNA interactions is made 
difficult by the remodeling of RNA structure upon drug binding, due to the inherent 
flexibility of nucleic acids.         
 The HCV internal ribosome entry site (IRES) located at the 5’ UTR of the viral 
RNA (Figure 1.2) has become a most attractive target, due to the structural and functional 
data available and also because of the conservation of IRES among HCV genotypes.3 
These IRES structures are also found in viral pathogens such as polio, foot-and-mouth 
disease, and swine fever virus.5 IRES mediates the initiation of viral-RNA translation in a 
cap-independent manner, and is also important for HCV RNA replication.7 Domain II of 
the HCV IRES has a 90o bent helical structure that is conserved in HCV and related 
viruses such as swine fever virus, and appears to be essential for the function of the 
IRES.8            
 A series of small-molecule HCV replication inhibitors based on a benzimidazole 
core has been reported.7 These molecules bind to the domain IIa of the HCV IRES, with 
low micromolar affinities. Mass spectrometry-based high throughput screening led to the 
identification of the benzimidazole hit 1.1 (Figure 1.3) with modest affinity and 
selectivity against the domain IIA 29-mer. In their attempts to optimize the structure, 
Seth et al.7 found that the dimethylamino head group on the tether at N1 to be crucial for 
RNA binding. When the dimethylamino group was replaced by other cationic head 
groups such as pyrrolidino, diethylamino and morpholino slight to substantial losses of 
binding affinity were observed.7         
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Figure 1.2. Structure of HCV IRES RNA8 
 
 In their attempts to modify the benzimidazole core, Seth et al.7 realized that a 
methoxy group at C6 in 1.2 resulted in a slight improvement of the binding affinity. 
Furthermore, introduction of a 3-(dimethylamino)propyloxy side chain at C6 in 1.3 
resulted in roughly 10-fold increase in binding affinity and a 5-fold increase in 
selectivity. They found out that the increase in binding affinity is due to the 2-amino 
group and the cationic side chains at N1 and C6, involving specific interactions with the 
RNA. Constraining the C6 side chain and N1 side chain to the benzimidazole core, 
shown in 1.4, 1.5 and 1.6, resulted in a spectacular increase in binding affinity. In 
addition, these molecules reduced HCV RNA levels at low micromolar concentrations in 
an HCV replicon assay.7 
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Figure 1.3. Benzimidazole based HCV inhibitors 
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Studies8 on the mechanism of action of the benzimidazoles revealed that HCV 
replication inhibition is due to the changes in IRES structure on inhibitor binding. Isis-11 
(1.4) binds specifically to the domain IIa bulge, displacing key nucleotide residues within 
the bulge region and affecting the stacking interactions, which ultimately results in a 
major structural reorganization. As it has been observed in solution and crystal form, 
inhibitor bound RNA structure has a straight form, in contrast to the bent form of free 
RNA. This structural change is further evident from large chemical shift changes in the 
NMR spectra of the inhibitor and conserved bulge region of RNA in both free and bound 
states. In addition, fluorescence intensity changes were measured in the modified bulge 
region, in which adenosine residues were replaced with 2-aminopurine. Inhibitor binding 
results in a large increase in fluorescence in the 5’ end, due to the interruption of stacking 
interactions, whereas quenching of fluorescence in the 3’ end suggests new stacking 
interactions. The investigations on the crucial functional groups of benzimidazole based 
HCV inhibitors revealed (from crystal structures) that the two dimethylamino groups 
replace two discrete metal ions in the divalent metal sites of RNA. The benzimidazole 
ring acts as a rigid linker for the two dimethylamino chains and involves RNA binding 
via π-stacking. Interestingly, the inhibitor binds with low micromolar affinity despite 
lacking any specific hydrogen bonding interactions, opening up the way to further 
optimize these molecules to create a new class of highly potent and specific HCV 
therapeutics.8 
The Rainier group, in collaboration with Davis, Cheatham and Hagedorn groups9 
of University of Utah, plans to reach the goal of developing novel, efficient, small 
molecule HCV therapeutics. The Rainier group plans on increasing the scope of potential 
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HCV inhibitors by synthesizing molecules centered around indoles, quaternary 
substituted indolines, and quaternary substituted thioindolines.  
The Rainier group has previously reported the synthesis of quaternary substituted 
indolines and thiopyranylindolines by Rh(II) mediated diazo decomposition. For 
instance, thiopyran 1.7 was coupled with vinyl diazoester in the presence of Rh2(OAC)4 
to give the corresponding thiopyranylindoline 1.8 in high yield and high 
diastereoselectivity (Scheme 1.1).10 Similarly, 2-thioindole 1.9 was reacted with vinyl 
diazoester in the presence of catalytic amount of Rh(II) to give indoline  1.10 from a 
[3,3]-sigmatropic rearrangement (Scheme 1.2).11 Subsequent reaction with TFA gave the 
desired pyrroloindoline 1.11. These reactions are in general high yielding, highly 
stereoselective and tolerate different substitution patterns, giving rise to a rich array of 
substrates. Thus we were hopeful that we could create a library of promising HCV 
inhibitors. The first chapter of this thesis is focused on the studies directed towards the 
synthesis of potential HCV inhibitors, based on quaternary substituted indolines. 
 
 
Scheme 1.1. Thiopyranylindoline synthesis 
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Reterosynthesis 
Our initial intention was to synthesize a series of potential inhibitors centered on 
pyrroloindoline 1.12 (Figure 1.4). Our targeted indoline compounds were docked into the 
RNA binding site (Figure 1.5) by Dr. Tom Cheatham,9 and proved to be promising HCV 
inhibitors. From the molecular docking studies, our targeted indoline compound 1.12.a 
has a score value of -13.2 kcal/mol compared to -10.4 kcal/mol of the benzimidazole 
compound 1.13 (Figure 1.6). These values are comparable with the known benzimidazole 
based inhibitors7, which compelled us to investigate the synthesis of a library of 
inhibitors based on pyrroloindoline 1.12.  
 
 
Figure 1.4. Targeted pyrroloindoline based HCV inhibitors 
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It was envisioned that 1.12 would arise from the final side chain installation by 
phenolic etherfication or carbamoylation between 1.14 and the respective side chain R2 
(Scheme 1.3). Deprotection of the Boc group of thioindoline 1.15 and subsequent 
cyclization would provide pyrroloindoline 1.14. The tertiary amine group of 1.15 would 
arise from functionalization of vinylic ester in 1.16. Rh(II) mediated [3,3]-sigmatropic 
rearrangement between 2-thioindole 1.17 and vinyl diazoester 1.18 would give 
thioindoline 1.16. 
 
                                            Results and Discussion          
           Studies towards synthesis of pyrroloindoline core   
 Our initial goal was to synthesize serotonin. Several attempts to synthesize 
serotonin have been reported in the literature, including biotransformations, long 
sequence synthesis, and a concise synthesis by Yang and Cao (Scheme 1.4).12 When we 
were attempting to follow their procedure, we were unable to reproduce their initial step 
of oxidation of indole 1.19 to 5-hydroxyindole 1.20.  Then the second step of alkylation 
of 1.20 with chloroethylamine hydrochloride, to give serotonin 1.21, was attempted with 
commercially available 5-hydroxyindole, which was also unsuccessful. Protection of     
5-hydroxy group of 1.20 with TBSCl and subsequent alkylation attempts only led to the 
recovery of the starting material. 
Synthesis of tryptamine and tryptamine derivatives by reduction of                       
3-indoleglyoxylamide has been reported13 previously (Scheme 1.5). The approach by 
Woodward,13a Vanderwerff,13b and Stoltz13c involved synthesis of 3-indoleglyoxalyl 
chloride by reaction of indole 1.22 with oxalyl chloride.  




Scheme 1.3. Reterosynthetic analysis  
 
 




Scheme 1.4. Synthesis of serotonin by Yang and Cao 





Scheme 1.5. Synthesis of tryptamine derivatives   
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 Subsequently, the glyoxalyl chloride was converted into the corresponding primary 
amide to provide 3-indoleglyoxylamide 1.23. Reduction with LiAlH4 gave tryptamine 
1.24 (Scheme 1.5). 
 Our attempt to synthesize serotonin using the above method involved conversion 
of 5-hydroxyindole 1.25 into indoleglyoxylamide 1.26 in 78% yield (Scheme 1.6). 
Subsequently, reduction of 1.26 with LiAlH4 gave a mixture of the starting material 1.26 
and serotonin 1.27 from the crude NMR. Unfortunately, it was difficult to reproduce the 
reduction step. Thus we started our synthesis with commercially available serotonin due 
to the time restraints.  
                                                              
	  
	  
Scheme 1.6. Synthesis of serotonin via indoleglyoxylamide 
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 During the course of our synthesis, Barsanti et al.14 reported a concise approach 
for the synthesis of tryptamine derivatives using Fischer indole synthesis.  They utilized 
phenyl hydrazine derivatives 1.28 with bis-ethoxyacetal 1.29, to give phthalimide 
protected amine 1.30, which on deprotection, using hydrazine, afforded the tryptamine 
derivatives 1.31 (Scheme 1.7).     
 Initially, Boc protection of serotonin hydrochloride 1.32 afforded 1.33, which 
after TBS protection provided 1.34 (Scheme 1.8). Then, 1.34 was reacted with PhSCl to 
give 2-thioindole, 1.17. Vinyl diazo compound was prepared from t-butylacetoacetate 
1.35 in three steps (Scheme 1.9).15 Reaction of 1.35 with diazo transfer reagent ABSA 
gave 1.36. NaBH4 reduction of 1.36 gave the corresponding secondary alcohol, which on 




Scheme 1.7. Synthesis of tryptamine derivatives by Barsanti et al. 




































Scheme 1.9. Synthesis of vinyl diazoester 
	   	   	   19 	  
	  
2-Thioindole 1.17 was reacted with vinyl diazo compound 1.37 in the presence of 
catalytic Rh2(OAc)4, to give indoline 1.38 from a [3,3]-sigmatropic rearrangement 
(Scheme 1.10). Although 1.37 is known to be unstable, we were thrilled at the high yields 
observed when freshly prepared 1.37 was slowly added to the reaction. In our attempts to 
scale up the reaction (up to 3 g scale of 1.34), we were pleased by the fact that yields 
were unaffected.          
 Vinylic ester compound 1.38 was reduced by (iBu)2AlH, to give the  the allylic 
alcohol compound 1.39. In order to make the allylic tertiary amine compound 1.40, 1.39 
was reacted with MsCl to form the corresponding allylic mesylate, which was 
subsequently reacted with dimethylamine to give 1.40 (Scheme 1.11).16 
 Pyrroloindoline 1.41 could be obtained by Boc group removal and the subsequent 
cyclization of thioindoline 1.40 (Scheme 1.12). In fact, similar cyclizations have been 
reported previously by the Rainier group (Scheme 1.2).11 For example, the NaH mediated 
cyclization of thioindoline 1.42 provided pyrroloindoline 1.43 and 1.45 (Scheme 1.13).17 
 
	  
Scheme 1.10. Synthesis of thioindoline from diazo decomposition 




Scheme 1.11. Synthesis of allylic dimethylamine compound 	  
 
 
	  	   Scheme 1.12. TFA mediated cyclization to form pyrroloindoline	  











R = Boc; 1.43
R = H; 80%; 1.44 	   	  	  	   Scheme 1.13. NaH mediated cyclization to give pyrroloindoline 
                                                                                                                                           
 To our surprise, when we attempt to cyclize 1.40, we only isolated an unidentified 
compound. After comparing 1.40 with the previous substrates 1.10 and 1.42, we came to 
the conclusion that the tertiary amine was the problem. Therefore, cyclization was 
attempted with the allylic alcohol substrate 1.39 to give 1.45, under both TFA and NaH 
conditions (Scheme 1.14). To our disappointment, in both attempts, instead of 1.45, we 
were still able to isolate the same unidentified compound. Attempts to cyclize the vinyl 
ester compound 1.38 were also unsuccessful. 
      
	  
Scheme 1.14. Attempted cyclizations to obtain pyrroloindoline 
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When comparing 1.39 with 1.42, other than the two methyl groups, the major 
difference is the 5-OH substituent in 1.39. Thus, with the thought that the activation of 
the ring by the hydroxyl substituent leads to the unexpected observations, we decided to 
protect the phenol with an electron withdrawing protecting group. Removal of the TBS 
group from 1.39, protecting with a tosyl group, gave compound 1.46. Unfortunately, 
attempts to cyclize 1.46 with TFA to give 1.47 were not successful either (Scheme 1.15).                
 More than a dozen times to cyclize under different conditions were attempted 
using 1.39. For example, instead of TFA to remove the Boc group, Lewis acids like 
TMSI, TMSOTf and SnBr2 and also heat were used. Although we were not able to 
successfully isolate the desired compound, it was possible to observe the product in the 
crude 1H NMR when a nonaqueous work up was carried out after the reaction, or when 
Amberlyst-21 was used to quench the reaction.18        
 
 
Scheme 1.15. Attempted cyclization on tosyl protected thioindoline 
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Finally, the amount of aqueous NaHCO3 used in the neutralization process during 
the work up proved to be critical. When a large excess was used, no product was isolated. 
When small quantities were used, 1.48 was isolated in 76% yield (Scheme 1.16). 
Attempts to deprotect the TBS group in 1.48 to give 1.49 led to the same unidentified 
compound that was observed previously.      
 Interestingly, deprotection of the TBS group of 1.39 and subsequent cyclization 
resulted 1.49 (TC 4.121) in 85% yield (Scheme 1.17). Inspired by this outcome, we 
subjected 1.40 to TBAF to afford 1.50 in a 95% yield and cyclization with TFA provided 




Scheme 1.16. Synthesis of pyrroloindoline via TFA mediated cyclization 
	   	   	   24 	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To further expand the reaction scope, we focused our attention on generating a 
series of allylic tertiary amines from 1.39. The allylic mesylate from 1.39 was subjected 
to secondary amines (R2NH) to give 1.52 (a-e) (Scheme 1.19). TBAF mediated 
deprotection of the TBS group provided 1.53 (a-e), which on reaction with TFA gave the 
respective pyrroloindoline compounds 1.54 (a-e).       
            
   Studies towards phenolic etherification   
 Reaching our final target compounds required the installation of the phenolic 
ether side chain. For this purpose we thought to perform the alkylation with a side chain 
having a tertiary amine in one terminus, and a leaving group on the other end. For 
instance, Sahu et al. have reported the formation of different basic ether side chains by 
alkylation of phenol.19 Reaction of 1.55 with the corresponding ammonium hydrochloride 
in the presence of K2CO3 in acetone provided 1.56 with the respective ether side chain 
(Scheme 1.20).         
 In addition, Mahboobi et al.20 were able to alkylate the 5-hydroxy indole 
derivative 1.57 with the alkyl halide side chain 1.58 in the presence of K2CO3 in acetone 
(Scheme 1.21).         
 However, when we attempted to alkylate 1.50 to give 1.59, using 
dimethylaminepropyl chloride (1.60.a) or iodide (1.60.b) under a number of different 
conditions including the Finklestein conditions,21 we were not able to form the phenolic 
ether bond (Scheme 1.22). Most of the time we were able to recover only the starting 
material or observed decomposition.        
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R2NH	  	   Number	   Yield	  
Diethylamine 1.52 a 85–90% 
Pyrrolodine 1.52 b 85–90% 
Piperidine 1.52 c 90% 
Morpholine 1.52 d 85% 
N,N,N’-Trimethyl-1,3-propanediamine 1.52 e 80% 
 
Scheme 1.19. Attempted synthesis for a series of pyrroloindolines 
       
           
            
	   	   	   27 	  
	  
 




Scheme 1.21. Phenolic alkylation by Mahboobi et al.                                                                                            
   





1.60 a, KOH, CH3CN, Bu4NHSO4 Recovered 1.50 
1.60 a, NaH, DMF, TBAI, 80 oC Decomposition and recovered 1.50 
1.60 a, K2CO3, Acetone, reflux Recovered 1.50 
1.60 a, K2CO3, NaI, DMF, 110 oC, Microwave Decomposition and recovered 1.50 
1.60 b, NaH, Acetone Recovered 1.50 
                              
 Scheme 1.22. Some attempted phenolic etherification conditions   
           
 Meanwhile, we attempted the alkylation of 1.50 with 1,3-propanediol-di-p-
tosylate 1.61 (Scheme 1.23). We were able to isolate the product 1.62, but only in low 
yield. Several attempts to enhance the yield were not successful. Although we assumed 
that the low yields could be either due to dimerization, polymerization, or formation of 
quaternary ammonium salts, we were not able to isolate any of these. In an attempt to 
displace the tosyl group of 1.61 in neat pyrrolidine, we observed the possible formation 
of product 1.62 from the crude 1H NMR through the disappearance of tosyl group.              
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                          Scheme 1.23. Synthesis of phenolic ether    
              
Harris et al., in their studies with quinazoline, have used Mitsunobu conditions for 
phenolic alkylation with basic side chains (Scheme 1.24).22 Noguchi et al., in their studies 
with Factor Xa, have reported Mitsunobu conditions or NaH with a tosylated side chain 
for the phenolic alkylation (Scheme 1.25).23       
 Our studies, though we used Mitsunobu conditions for the phenolic alkylation, 
were not successful. When we subjected 1.50 to PPh3 and DEAD or DIAD and the 
respective side chain, the starting material 1.50 was recovered (Scheme 1.26). 
 In addition, attempts to tosylate the primary alcohol in 1.64 to give 1.65 were also 
not successful, for it gave various byproducts (Scheme 1.27). As we expected, this could 
possibly be due to the polymerization or salt formation.  


























Scheme 1.25. Phenolic etherification by Noguchi et al. 
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Basic group (RN-) Conditions 
Et2N- PPh3, DIAD, THF, RT 
	  
PPh3, DIAD, THF, RT 
Et2N- PPh3, DEAD, THF, RT, sonication 
                                     




Scheme 1.27. Attempted synthesis for a tosylated side chain 
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                                      Studies towards phenolic carbamoylation   
 Carbamate side chains are prevalent in molecules with significant biological 
activity, such as in cholinesterase inhibitors.24a,b,c Gillies et al., in their studies on  
biodegradable polymers, reported the formation of a carbamate bond between phenol and 
a secondary amine using p-nitrophenylchloroformate (Scheme 1.28).25   
 With curiosity about how a carbamate side chain would influence the activity of 
our target compounds, we decided to subject the phenol of 1.50 to carbamoylation 
conditions (Scheme 1.29). For this purpose, 1.50 was reacted with p-
nitrophenylchloroformate and attempts to isolate the product of this reaction were not 
successful. Therefore, we subjected the reaction mixture immediately to N,N,N’-
trimethyl-1,3-propanediamine. However, we were not able to successfully isolate the 




Scheme 1.28. Phenolic carbamoylation by Gillies et al. 
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Scheme 1.29. Attempted synthesis for a carbamate side chain 
   
                        Studies towards synthesis of pyrrole side chain                            
 In order to make the basic side chain with the terminal pyrrole group, our initial 
plan was to react 2-substituted methylpyrrole 1.67 with bromopropanol or bromobutanol 
1.68, to give 1.69 (Scheme 1.30). However, when we attempted to synthesize 1.67, we 
were only able to mainly isolate the dimer 1.70 (Scheme 1.31).26   
 Fairhurst et al., in their studies of the Mannich reactions of oxazolidines, reported 
the synthesis of 1.71.a from N-methylpyrrole and 3-methyl-1,3-oxazolidine (Scheme 
1.32).27 They also observed the formation of di-substituted product 1.71.b when the 
reaction was performed using trichloromethylsilane.      
 Thus we synthesized secondary amine 1.72 for our studies (Scheme 1.33).28 The 
reaction of methylpyrrole with formaldehyde, methylpropanol 1.72, and TsOH provided 
1.73, but only in low yield (Scheme 1.34). When TsOH was replaced with CSA in 
MeOH, we observed the deprotection of the TBS ether of 1.73. TBAF deprotection of the 
silyl ether in 1.73 and tosylation of the primary alcohol provided the target side chain 
1.74.  
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1.67 1.70  
Scheme 1.31. Attempted synthesis for 2-substituted methylpyrrole 

















Me3SiCl 73%  
Scheme 1.32. Synthesis of 2-substituted methylpyrrole by Fairhurst et al. 
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Scheme 1.34. Synthesis of pyrrole side chain	  	  
Conclusion	  
 Our main goal was to synthesize a series of analogues that would be evaluated for 
activity against HCV. Based on the preliminary data that we would obtain after screening 
of TC 4.121, and TC 4.122, we should be able to further optimize the structure of our 
inhibitors for enhanced affinity and activity for HCV RNA. It has been observed that 
compounds based on a benzimidazole or indole core act as non-nucleoside inhibitors of 
the HCV NS5B polymerase.3 Thus it would be useful in the future to screen our 
compounds for HCV RNA IRES, as well as viral enzymes. In addition, screening against 
	   	   	   36 	  
	  
other pathogenic viral IRES would also be valuable for diseases like HIV. Furthermore, 
as pyrroloindolines are well known for their biological activity,29 it would be worthwhile 
to screen our molecules against other medicinally important targets like cancer.  
 Further efforts are required for installing the phenolic side chain and for 
optimizing the techniques for isolation of the pyrroloindoline substrates. As studies with 
these molecules are currently undergoing, it could be possible to realize whether 
difficulties observed are due to the unpredictable functionality of these compounds, or 
due to the issues associated with the technique. Also we should note the difficulty 
associated with purification of these pyrroloindolines. Most of the time, purification was 
done using preparative silica gel TLC, but it results in a significant decomposition of the 
product. Purification using neutral or basic alumina was not very successful either. 
Presumably, purification using reverse phase silica or preparative HPLC would be more 
efficient.          
 Current studies from the Rainier group on pyrroloindolines substrates based on 
1.75 could further enhance the substrate scope (Figure 1.7).30 Moreover, future studies 
with thio-pyranyl/furanyl indolines 1.76 and oxo-pyranyl/furanyl indolines 1.77 would 
provide us with the prospect of a library of potential inhibitors. In conclusion, we hope 
our efforts would be successful in achieving our ultimate goal of discovering an effective 
drug for HCV infection.         
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Figure 1.7. Targeted library of potential HCV inhibitors 
  
                                                                Experimental Section    
 Ether and THF were distilled from sodium and benzophenone. CH2Cl2, Hexane, 
Et3N, MeOH, CH3CN were distilled from CaH2.  All other reagents were used without 
further purification unless otherwise stated. Glassware for the reactions was oven dried or 
flame dried and cooled prior to use. All reactions were run under an atmosphere of 
nitrogen or argon unless otherwise stated. Thin layer chromatography was performed on 
Silica gel 60 F254 plates eluting with the solvent indicated, visualized by a 254/ 365 nm 
UV lamp, and stained with solutions p-anisaldehyde, potassium permanganate, Seebach’s 
stain or iodine chamber. Column chromatography was performed with 40–63 µm silica 
gel, activated neutral alumina or basic alumina. Yields were calculated for material 
judged homogenous by thin layer chromatography and NMR. Compounds were named 
using CS ChemBioDraw Ultra 12.0.  NMR spectra were acquired on the Varian Unity-
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300, VXR 500 or i400 spectrometers. Chemical shifts for 1H NMR spectra are reported in 
parts per million relative to the signal of residual CHCl3 at 7.27 ppm or the center line of 
the residual MeOH pentet at 3.31 ppm. Chemicals shifts for 13C NMR spectra are 
reported in parts per million relative to the center line of the CDCl3 triplet at 77.23 ppm 
or the center line of the CD3OD septet at 49.15 ppm. The abbreviations s, d, dd, ddd, dt, t, 
td, q and m stand for the resonance multiplicity singlet, doublet, doublet of doublet, 
doublet of doublet of doublet, doublet of triplet, triplet, triplet of doublet, quartet and 
multiplet respectively. IR spectra were obtained from Nicolet 380 FT-IR spectrometer. 
Mass spectra were recorded at the Mass Spectrometry facility in the Department of 
Chemistry of the University of Utah.        
            
                   Reaction procedures and characterizations of the products 
Synthesis of tert-butyl(2-(5-((tert-butyldimethylsilyl 
)oxy)-2-(phenylthio)-1H-indol-3-yl)ethyl) carbamate 1.17. To a solution of serotonin 
hydrochloride (2.527 g, 11.881 mmol) in CH2Cl2 (100 ml), Boc2O (2.593 g, 11.881 
mmol) and Et3N (5 ml, 35.642 mmol) were added at 0 ºC. After stirring at RT overnight 
the reaction was quenched with saturated NH4Cl (50 ml). After extraction of the aqueous 
phase with CH2Cl2 (3 x 100 ml), combined organic extracts were washed with brine, 
dried (Na2SO4) and concentrated to afford mono Boc protected serotonin 1.33, which was 
used forward without further purification.             
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 To the above crude product 1.33  (11.881 mmol) in DMF (10 ml) under an 
atmosphere of N2, TBSCl (2.418 g, 16.039 mmol) and imidazole (2.346 g, 34.454 mmol) 
were added at 0 ºC.  After stirring at RT overnight the reaction was quenched with 
saturated NH4Cl and extracted the aqueous phase with Et2O (3 x 100 ml). The combined 
organic extracts were washed with brine, dried (Na2SO4) and concentrated to afford 1.34, 
which was used forward without further purification.                     
 To the above crude product 1.34 (11.117 mmol) in CH2Cl2 under an atmosphere 
of N2, PhSCl (1.896 g, 13.114 mmol) was added dropwise at 0 ºC.  After stirring at 0 ºC 
for 1.5 h, the reaction was quenched with NaHCO3 and extracted with CH2Cl2. The 
combined organic extracts were washed with brine, dried (Na2SO4) and concentrated. 
The crude material was purified by neutral silica flash column chromatography to afford 
4.879 g (88%) of 1.17 as a white foam and some starting material, 1.34. (Rf = 0.8 in 3: 7 
Ethyl acetate: Hexane).      
 1H NMR (300 MHz, CDCl3) δ 8.21 (broad s, 1 H), 7.26- 7.23 (m, 2 H), 7.19- 7.14 
(m, 2 H), 7.09 (d, J = 8.1 Hz, 3 H), 6.83 (dd, J = 8.7, 2.4 Hz, 1 H), 4.57 (broad s, 1 H), 
3.39 (q, J = 5.4 Hz, 2 H), 3.01 (t, J = 6.4 Hz, 2 H), 1.42 (s, 9 H), 1.04 (s, 9 H), 0.24 (s,     
6 H). 13C NMR (125 MHz, CDCl3) δ 156.2, 149.6, 137.4, 133, 129.4, 128.7, 126.8, 
126.0, 123.3, 120.2, 118.1, 111.7, 108.7, 79.2, 41.2, 28.6, 26.1, 25.5, 18.4, -4.1. IR (neat): 
3417 cm-1, 3290 cm-1, 2955 cm-1, 2929 cm-1, 2857 cm-1, 1691 cm-1, 1250 cm-1, 1168 cm-1. 
LRMS (ESI) m/z calc’d for C27H38N2O3SSi (MH+): 499.2, (MNa+): 521.2, (MK+): 
537.2; found (MH+): 499.2, (MNa+): 521.2, (MK+): 537.2. 
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Synthesis of (E)-tert-butyl 4-(3-(2-((tert-butoxycar 
bonyl)amino)ethyl)-5-((tertbutyldimethylsilyl)oxy)-2-(phenylthio)-3H-indol-3-yl)but-
2-enoate 1.38. To a solution of 1.17 (0.735 g, 1.474 mmol) and Rh2(OAc)4 (0.033 g, 
0.074 mmol) in CH2Cl2 (50 ml) at RT under an atmosphere of N2, was slowly added a 
solution of freshly prepared  vinyl diazo 1.37 (0.588 g, 3.498 mmol) in CH2Cl2 (10 ml) 
from a syringe pump for 10 h. Following the addition reaction was stirred at RT for 
further 28 h and concentrated.  The crude material was purified by neutralized silica flash 
column chromatography (1:9 EtOAC: Hexane) to afford 0.876 g (93%) of 1.38 as a 
yellowish brown oil and 0.042 g (5.6 %) of 1.17. (Rf = 0.5 in 3: 7 Ethyl acetate: Hexane). 
 1H NMR (500 MHz, CDCl3) δ 7.68-7.66 (m, 2 H), 7.45-7.4 (m, 3 H), 7.26 (dd,     
J = 8.4, 1.4 Hz, 1 H), 6.75 (d, J = 8.1, 1 H), 6.72 (s, 1 H), 6.35-6.29 (m, 1 H), 5.75 (d,      
J = 15.8 Hz, 1 H), 4.3 (broad s, 1 H), 2.78-2.74 (m, 3 H), 2.65 (dd, J = 13.8, 8.1 Hz, 1 H), 
2.21(broad t, 2 H), 1.43 (s, 18 H), 1.00 (s, 9 H), 0.20 (s, 6 H). 13C NMR (125 MHz, 
CDCl3) δ 181.2, 165.2, 155.8, 153.5, 149.4, 141.8, 140.4, 134.7, 129.5, 128, 127.2,125.1, 
120.4, 119.9, 114.4, 80.4, 79.4, 62, 53.8, 41.4, 37.6, 36.7, 28.6, 28.3, 25.9, -4.2. IR (neat): 
3359 cm-1, 2957 cm-1, 2930 cm-1, 2858 cm-1, 1712 cm-1, 1463 cm-1, 1157 cm-1.  LRMS 
(ESI) m/z calc’d for C35H50N2O5SSi (MH+): 639.3, (MNa+): 661.3, (MK+): 677.3; found 
(MH+): 639.3, (MNa+): 661.3, (MK+): 677.3. 
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Synthesis of (E)-tert-butyl (2-(5-((tert-butyldimethy 
lsilyl)oxy)-3-(4-(dimethylamino)but-2-en-1-yl)-2-(phenylthio)-3H-indol-3-yl)ethyl) 
carbamate 1.40. To a solution of vinyl ester 1.38 (2.765 g, 4.327 mmol) in CH2Cl2 (70 
ml), DIBAl-H (8.7 ml, 12.982 mmol) was added dropwise at 0 ºC. After stirring at RT 
overnight the reaction was quenched with CH2Cl2: H2O: satd. Rochelle salt (12 ml: 12 
ml: 12 ml) at 0 °C. After stirring at 0 °C for 1.5 h, the mixture was extracted with CH2Cl2 
(3 x 50 ml). The combined organic extracts were washed with brine, dried (Na2SO4) and 
concentrated to afford the allylic alcohol 1.39, which was used forward without further 
purification.                              
                                                 
                      General procedure A     
 To a solution of allylic alcohol 1.39 (0.637 g, 1.12 mmol) in THF (20 ml), Et3N 
(0.47 ml, 3.359 mmol) and MsCl (0.17 ml, 2.239 mmol) were added at 0 °C. After 
stirring at 0 °C for about 20 min, the reaction was filtered and washed with THF. To the 
combined mixture of filtrate and washings Me2NH (11.2 ml, 22.392 mmol) was added at 
0 °C. After stirring at RT overnight the reaction was filtered, washed with THF and 
concentrated. The crude mixture was used forward without further purification or if 
necessary passed through a neutral alumina column to afford 0.467 g (70%) of 1.40 as a 
yellowish brown oil. (Rf = 0.45 in 6: 1 CH2Cl2: MeOH in silica)    
 1H NMR (300 MHz, CDCl3) δ 7.7-7.67 (m, 2 H), 7.45-7.43 (m, 3 H), 7.21 (d,       
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J = 9.1 Hz, 1 H), 6.72-6.69 (m, 2 H), 5.6-5.5 (m, 1 H), 5.12-5.02 (m, 1 H), 4.27 (broad s, 
1 H), 2.91-2.84 (m, 2 H), 2.77 (q, J = 6.7 Hz, 2 H), 2.64 (d, J = 7.1 Hz, 2 H), 2.19 
(partially obscured t, J = 6.1 Hz, 2 H), 2.14 (s, 6 H), 1.4 (s, 9 H), 0.99 (s, 9 H), 0.2 (s,      
6 H). 13C NMR (125 MHz, CDCl3) 181.6, 155.7, 153.2, 149.4, 142.4, 134.4, 131.9, 
129.5, 129.3, 128.2, 126.4, 119.8, 119.3, 114.2, 79.1, 62.6, 61.6, 45.4, 45, 41.8, 37.7, 
33.2, 29.8, 28.5, 25.8, -4.3. IR (neat): 2927 cm-1, 2855 cm-1, 1700 cm-1, 1464 cm-1, 1175 
cm-1. LRMS (ESI) m/z calc’d for C33H49N3O3SSi (MH+): 596.3, (MNa+): 618.3; found 
(MH+): 596.3, (MNa+): 618.3. 
 
General procedure B 
 To a solution of allylic alcohol 1.39 (0.021 g, 0.037 mmol) in THF (4 ml) TBAF 
(0.07 ml, 0.073 mmol) was added at 0 °C. After stirring at 0 °C for about 45 min the 
reaction was quenched with saturated NH4Cl and extracted the aqueous phase with 
EtOAc (3 x 10 ml). The combined organic extracts were washed with brine, dried 
(Na2SO4) and concentrated to afford a crude oil, which was purified using silica gel 
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  Synthesis of allylic hydroxy pyrroloindoline 1.49. 
General procedure C 
To the above crude product	   (0.022 g, 0.048 mmol) in CH2Cl2 (2 ml) under an 
atmosphere of N2, TFA (0.5 ml,) was added dropwise at 0 ºC. After the addition reaction 
was stirred at 0 ºC for 15 min. Then the reaction was slowly warmed to RT, stirred for 
another 45 min and concentrated. After trituration of the crude reaction mixture with 
ether, reaction was purified using silica gel PTLC (1: 62: 62 TFA: CH2Cl2: MeOH). 
Product was further purified using silica gel PTLC (1: 53: 53 TFA: CH2Cl2: MeOH) to 
afford 7 mg (85%, two steps from 1.39) of TC 4.121 as a yellowish brown oil. (Rf = 0.75 
in 1: 62: 62 TFA: CH2Cl2: MeOH).        
 1H NMR (500 MHz, CD3OD) δ 6.81 (d, J = 8.3 Hz, 1 H), 6.72 (d, J = 1.1, 1 H), 
6.64 (dd, J = 8.3, 1.1 Hz, 1 H), 5.54 (td, J = 15.1, 5.4 Hz, 1 H), 5.38-5.32 (m, 1 H), 4.2 
(dt, J = 11.2, 4.9 Hz, 1 H), 3.94 (dd, J = 10.7, 8.8 Hz, 1 H), 3.86 (d, J = 4.9 Hz, 2 H), 2.57 
(dd, J = 13.7, 7.3 Hz, 1 H), 2.44 (dd, J = 12.2, 4.9 Hz, 1 H), 2.36 (dd, J = 13.2, 7.3 Hz,     
1 H), 2.28 (dd, J = 21, 9.8 Hz, 1 H). 13C NMR (125 MHz, CD3OD) 163.1, 136.9, 124.3, 
121.9, 119.5, 117.2, 116.4, 114.8, 113.6, 63.1, 54.4, 49.4, 40.3, 34.3. IR (neat): 1679   
cm-1, 1208 cm-1, 1142 cm-1. LRMS (ESI) m/z calc’d for C14H16N2O2 (MH+): 245.1; found 
(MH+): 245.0. 	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 Synthesis of allylic dimethylamino pyrroloindoline 1.51. 
Synthesized according to the General procedure B using allylic amine 1.40 (0.311 g, 
0.522 mmol) and TBAF (1.04 ml, 1.043 mmol) in THF (30 ml). The crude oil was passed 
through a neutral alumina column (20:1 CH2Cl2: MeOH) if necessary and used for the 
next step without further purification. 
 Pyrroloindoline synthesis was performed according to the General procedure C 
using above allylic amine (0.009 g, 0.019 mmol) and TFA (0.25 ml) in CH2Cl2 (1 ml). 
Reaction was purified using silica gel PTLC (1: 53: 53 TFA: CH2Cl2: MeOH) to afford   
4 mg (86%) of TC 4.122 as a yellowish brown oil. (Rf = 0.7 in 1: 62: 62 TFA: CH2Cl2: 
MeOH)          
 1H NMR (500 MHz, CD3OD) δ 6.90 (d, J = 7.7 Hz, 1 H), 6.83 (s, 1 H), 6.72 (d,    
J = 7.4 Hz, 1 H), 5.74-5.6 (broad m, 1 H), 5.6-5.46 (broad m, 1 H), 4.42-4.3 (broad m,    
1 H), 4.14-4.0 (m, 1 H), 3.6-3.53 (m, 2 H), 2.64 (s, 6 H), 2.58-2.4 (broad m, 4 H). 13C 
NMR (125 MHz, CD3OD) 180.9, 156.4, 137.2, 123.7, 119.8, 116.3, 116, 113.4, 111.1, 
62.3, 59.6, 59.5, 42.5, 40, 36.3. IR (neat): 1680 cm-1, 1209 cm-1, 1140 cm-1. LRMS (ESI) 
m/z calc’d for C16H21N3O (MH+): 272.2; found (MH+): 272.1 
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Synthesis of allylic piperidino indoline 1.52 c. 
Synthesized according to the General procedure A using allylic alcohol 1.39 (0.024 g, 
0.043 mmol), Et3N (0.015 ml, 0.107 mmol) and MsCl (0.008 ml, 0.085 mmol) in THF    
(4 ml). Subsequently, allylic mesylate was substituted by piperidine (0.08 ml, 0.854 
mmol). Neutral alumina flash column chromatography (20: 1 CH2Cl2: MeOH ) afforded 
0.025 g (90%) of 1.52 c as a yellowish brown oil. (Rf = 0.85 in 6: 1 CH2Cl2: MeOH).  
 1H NMR (500 MHz, CDCl3) δ 7.69-7.66 (m, 2 H), 7.45-7.41 (m, 3 H), 7.21 (d, J 
= 9.1 Hz, 1 H), 6.72 (partially obscured d, J = 9.1 Hz, 1 H), 6.69 (s, 1 H), 5.57-5.47 (m, 1 
H), 5.04-4.94 (m, 1 H), 4.27 (broad s, 1 H), 2.76 (m, 3 H), 2.69 (partially obscured d, J = 
8 Hz, 1 H), 2.60 (d, J = 7 Hz, 2 H), 2.22-2.04 (broad m, 6 H), 1.52-1.44 (partially 
obscured m, 6 H), 1.4 (s, 9 H), 0.99 (s, 9 H), 0.2 (s, 6 H). 13C NMR (125 MHz, CDCl3) δ 
181.7, 155.8, 153.4, 149.6, 142.5, 134.5, 131.6, 129.5, 129.3, 128.3, 126.6, 120, 119.5, 
114.3, 61.4, 60.6, 54.2, 53.6, 42, 38, 36.8, 29.9, 28.6, 25.9, 24.4, 21.3, -4.2. IR (neat): 
2931 cm-1, 2850 cm-1, 1713 cm-1, 1463 cm-1, 1274 cm-1. LRMS (ESI) m/z calc’d for 
C36H53N3O3SSi (MH+): 636.4, (MNa+): 658.4; found (MH+): 636.3, (MNa+): 658.4. 
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  Synthesis of indoline 1.52 e. Synthesized according 
to the General procedure A using allylic alcohol 1.39 (0.045 g, 0.079 mmol), Et3N (0.03 
ml, 0.198 mmol) and MsCl (0.01 ml, 0.158 mmol) in THF (8 ml). Subsequently, allylic 
mesylate was substituted by N,N,N’-trimethyl-1,3-propanediamine (0.23 ml, 1.582 
mmol). Silica gel PTLC (6: 1 CH2Cl2: MeOH) afforded 0.042 g (80%) of 1.52 e as a 
yellowish brown oil. (Rf = 0.8 in 6: 1 CH2Cl2: MeOH).     
 1H NMR (500 MHz, CDCl3) δ 7.68-7.66 (m, 2 H), 7.44-7.4 (m, 3 H), 7.2 (d, J = 
8.8 Hz, 1 H), 6.71 (partially obscured d, J = 8.8 Hz, 1 H), 6.69 (s, 1 H), 5.52-5.46 (m,      
1 H), 5.05-4.99 (m, 1 H), 4.26 (broad s, 1 H), 2.8-2.68 (m, 4 H), 2.63-2.54 (m, 2 H), 2.21-
2.15 (obscured m, 6 H), 2.19 (s, 6 H), 1.97 (s, 3 H), 1.54 (p, J = 7.3 Hz, 2 H), 1.39 (s,      
9 H), 0.98 (s, 9 H), 0.18 (s, 6 H). 13C NMR (125 MHz, CDCl3) δ 181.7, 155.7, 153.3, 
149.5, 142.5, 134.5, 131.8 129.4, 129.3, 128.3, 126.4, 119.9, 119.5, 114.3, 79.3, 59.9, 
58.1, 55.5, 48.5, 45.7, 41.9, 41.8, 37.9, 36.7, 35.4, 28.6, 25.9, 25.87, -4.2. IR (neat): 2928 
cm-1, 2856 cm-1, 1708 cm-1, 1463 cm-1, 1150 cm-1. LRMS (ESI) m/z calc’d for 
C37H58N4O3SSi (MH+): 667.4, (MNa+): 689.4; found (MH+): 667.4, (MNa+): 689.4. 
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Synthesis of allylic diethylamino indoline 1.53 a. 
Synthesized according to the General procedure A using allylic alcohol 1.39 (0.024 g, 
0.043 mmol), Et3N (0.015 ml, 0.107 mmol) and MsCl (0.008 ml, 0.085 mmol) in THF    
(4 ml). Subsequently, allylic mesylate was substituted by Et2NH (0.09 ml, 0.854 mmol). 
The crude mixture was passed through a neutral alumina column (9: 1 CH2Cl2: MeOH) if 
necessary and used for the next step without further purification. 	   The TBS group deprotection was performed according to the General procedure 
B using above allylic amine (0.0412 mmol) and TBAF (0.08 ml, 0.082 mmol) in THF    
(6 ml). Neutral alumina flash column chromatography (9: 1 CH2Cl2: MeOH) afforded 
0.017 g (81%) of 1.53 a as a yellowish brown oil. (Rf = 0.4 in 6: 1 CH2Cl2: MeOH).  
 1H NMR (500 MHz, CDCl3) δ 7.7-7.66 (m, 2 H), 7.43-7.4 (m, 3 H), 7.14 (d, J = 
8.4 Hz, 1 H), 6.93 (partially obscured d, J = 1.7 Hz, 1 H), 6.78 (partially obscured dd, J = 
8.4, 2 Hz, 1 H), 5.68-5.58 (m, 1 H), 5.29-5.2 (m, 1 H), 4.46 (broad s, 1 H), 3.35 (dd, J = 
13.1, 5.4 Hz, 1 H), 3.08 (dd, J = 13.1, 9 Hz, 1 H),  2.86-2.74 (partially obscured m, 2 H), 
2.68 (d, J = 7 Hz, 2 H), 2.63-2.45 (partially obscured m, 4 H), 2.17 (t, J = 6 Hz, 2 H), 
1.38 (s, 9 H), 1.1 (t, J = 7.4 Hz, 6 H). 13C NMR (100 MHz, CDCl3) δ 171.4, 155.9, 155.0, 
148.2, 144.5, 142.4, 134.5, 129.5, 129.3, 129.2, 129, 120, 115.3, 110.6, 77.8, 60.6, 54.4, 
45.7, 41.7, 38.1, 36.7, 28.6, 14.4. IR (neat): 2955 cm-1, 2918 cm-1, 2849 cm-1, 1273 cm-1. 
LRMS (ESI) m/z calc’d for C29H39N3O3S (MH+): 510.3, (MNa+): 532.3; found (MH+): 
510.3, (MNa+): 532.3. 
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 Synthesis of allylic pyrrolidino indoline 1.53 b. 
Synthesized according to the General procedure A using allylic alcohol 1.39 (0.024 g, 
0.043 mmol), Et3N (0.015 ml, 0.107 mmol) and MsCl (0.008 ml, 0.085 mmol) in THF 
(4 ml). Subsequently, allylic mesylate was substituted by pyrrolidine (0.07 ml, 0.854 
mmol). The crude mixture was passed through a neutral alumina column (9: 1 CH2Cl2: 
MeOH) if necessary and used forward without further purification. 	   The TBS group deprotection was performed according to the General procedure 
B using above allylic amine (0.043 mmol) and TBAF (0.09 ml, 0.085 mmol) in THF      
(8 ml). Neutral alumina flash column chromatography (9: 1 CH2Cl2: MeOH) afforded 
0.019 g (86%) of 1.53 b as a yellowish brown oil. (Rf = 0.4 in 6: 1 CH2Cl2: MeOH).  
 1H NMR (500 MHz, CDCl3) δ 7.68-7.67 (m, 2 H), 7.45-7.4 (m, 3 H), 7.17 (d, J = 
8.3 Hz, 1 H), 6.66 (d, J = 2 Hz, 1 H), 6.59 (dd, J = 8.3, 2.4 Hz, 1 H), 5.54-5.49 (m, 1 H), 
5.12-5.09 (m, 1 H), 4.39 (broad s, 1 H), 2.99 (dd, J = 12.2, 5.9 Hz, 1 H), 2.8 (partially 
obscured dd, J = 13.2, 7.8 Hz, 1 H), 2.77-2.73 (broad m, 2 H), 2.55 (d, J = 7.3 Hz, 2 H), 
2.28-2.23 (m, 4 H), 2.14 (t, J = 7 Hz, 2 H), 1.69 (broad s, 4 H) 1.4 (s, 9 H).    13C NMR 
(100 MHz, CDCl3) δ 180.6, 155, 148.1, 142.5, 134.5, 130.3 (broad), 129.5, 129.3, 128.3 
(broad), 120.1, 115.2, 110.6, 57.6, 53.4, 41.7, 37.9, 36.7, 33.9, 28.6, 23.4. IR (neat): 2956 
cm-1, 2917 cm-1, 2849 cm-1, 1707 cm-1, 1462 cm-1. LRMS (ESI) m/z calc’d for 
C29H37N3O3S (MH+): 508.3; found (MH+): 508.3.  
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 Synthesis of allylic morpholino pyrroloindoline 1.54 d. 
Synthesized according to the General procedure A using allylic alcohol 1.39 (0.024 g, 
0.043 mmol), Et3N (0.015 ml, 0.107 mmol) and MsCl (0.008 ml, 0.085 mmol) in THF 
(4 ml). Subsequently, allylic mesylate was substituted by morpholine (0.07 ml, 0.854 
mmol). The crude mixture was passed through a neutral alumina column (9: 1 CH2Cl2: 
MeOH) if necessary and used forward without further purification. 	   The TBS group deprotection was performed according to the General procedure 
B using the above allylic amine (0.043 mmol) and TBAF (0.09 ml, 0.085 mmol) in THF      
(8 ml). The crude oil was passed through a neutral alumina column (9: 1 CH2Cl2: MeOH) 
if necessary and used for the next step without further purification. 	   Pyrroloindoline synthesis was performed according to the General procedure C 
using above allylic amine (0.036 mmol) and TFA (0.3 ml) in CH2Cl2 (3 ml). Reaction 
was purified using silica gel PTLC (4: 1 CH2Cl2: MeOH) to afford 8 mg (75%) of 1.54 d 
as a yellowish brown oil. (Rf = 0.2 in 4: 1 CH2Cl2: MeOH).	  	  	   	   	  	   1H NMR (500 MHz, CD3OD) δ 6.71 (d, J = 8.2 Hz, 1 H), 6.65 (d, J = 2.2 Hz,      
1 H), 6.56 (dd, J = 8.2, 2.5 Hz, 1 H), 5.34-5.31 (m, 2 H), 4.04-3.99 (m, 1 H), 3.81 (dd, J = 
11.5, 8.2 Hz, 1 H), 3.62 (dd, J = 4.7, 4.4 Hz, 4 H), 2.89 (dd, J = 12.4, 3.3 Hz, 1 H), 2.72 
(dd, J = 12.9, 6 Hz, 1 H), 2.54- 2.46 (m, 2 H), 2.28 (partially obscured dd, J = 12.1, 5 Hz, 
1 H), 2.20 (partially obscured dd, J = 4.7, 4.4 Hz, 4 H), 2.1 (dd, J = 20.6, 10.4 Hz, 1 H). 
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IR (neat): 2922 cm-1, 2852 cm-1, 1676 cm-1, 1208 cm-1, 1137 cm-1. LRMS (ESI) m/z calc’d 
for C18H23N3O2 (MH+): 314.2; found (MH+): 314.2. 
 Synthesis of pyrrole side chain 1.74. To a solution of HCHO 
(0.01 ml, 0.096 mmol), amine 1.72 (0.019 g, 0.096 mmol) and TsOH.H2O (0.002 g, 0.008 
mmol) was added and stirred for 30 min. The mixture was slowly added into 
methylpyrrole (0.01 ml, 0.08 mmol) at 0 oC for 45 min. After stirring at RT overnight, the 
reaction was quenched with saturated NaHCO3 and extracted the aqueous phase with 
CH2Cl2 (3 x 15 ml). The combined organic extracts were washed with brine, dried 
(Na2SO4) and concentrated. The crude material was purified by neutralized silica flash 
column chromatography (1:9 EtOAC: Hexane) to afford 1.73.    
 To a solution of 1.73 (0.006 g, 0.021 mmol) in THF (1 ml), TBAF (0.04 ml, 
0.041mmol) was added at 0 oC. After stirring at 0 oC for 1 h the reaction was quenched 
with saturated NH4Cl and extracted the aqueous phase with CH2Cl2 (3 x 10 ml). The 
combined organic extracts were washed with brine, dried (Na2SO4) and concentrated. 
The crude material was purified using silica gel PTLC (6:4 EtOAC: Hexane). 
 To the above primary alcohol (0.003 g, 0.018 mmol) in CH2Cl2 (1 ml), TsCl 
(0.004 g, 0.021 mmol), Et3N (0.01 ml, 0.07 mmol) and catalytic amount of DMAP was 
added at 0 oC. After stirring at RT overnight the reaction was quenched with saturated 
NH4Cl and extracted the aqueous phase with CH2Cl2 (3 x 10 ml). The combined organic 
extracts were washed with brine, dried (Na2SO4) and concentrated. The crude material 
was purified using silica gel PTLC (3:7 EtOAC: Hexane) to afford 3 mg (53%) of 1.74 as 
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a brownish oil.          
 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8.4 Hz, 2 H), 7.35 (d, J = 8.4 Hz, 2 H), 
6.58 (s, 1 H), 6.02 (dd, J = 3.4, 2.7 Hz, 1 H), 5.94 (s, 1 H), 4.07 (t, J = 6.1, 6.7 Hz, 2 H), 
3.56 (s, 3 H), 3.36 (s, 2 H), 2.47 (s, 3 H), 2.38 (t, J = 6.7 Hz, 2 H), 2.08 (s, 3 H), 1.79 (tt, 
J = 7.1, 6.7 Hz, 2 H). 13C NMR (125 MHz, CDCl3) δ 144.8, 130.1, 129.9, 128.1, 128.0, 
122.7, 109.7, 106.4, 69.1, 54.4, 52.9, 41.7, 31.1, 27.0, 21.8. IR (neat): 3400 cm-1, 2924 
cm-1, 2854 cm-1, 1192 cm-1. LRMS (ESI) m/z calc’d for C17H24N2O3S (MNa+): 359.1, 
(MK+): 375.1; found (MNa+): 359.1, (MK+): 375.1. 
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STUDIES TOWARDS THE EPIDITHIODIKETOPIPERAZINE                 
ALKYLATION IN CHAETOMIN   
   
                                                                Introduction     
 2,5-Diketopiperazines (DKPs) are cyclic dipeptides ubiquitous in nature, and are 
attributed with a multitude of appealing biological activities, such as anti cancer activity, 
neuroprotective effects, antihelmintic properties, tryptase inhibition and oxytocin receptor 
antagonism.1 Enormous efforts have been reported for the synthesis of these alkaloids 
due to their fascinating architecture, coupled with their interesting biological activity.2 
Among the DKP targets are the fungal secondary metabolites, called ETPs 
(epipolythiodioxopiperazines), which contain sulfide bridges (di, tri or tetra ) across the 
3,6- positions of the DKPs.3 It is believed that the striking biological activities of these 
molecules are due to their sulfide bridges, which can directly conjugate to cysteine 
residues or generate reactive oxygen species by redox cycling. Most natural ETPs are 
derived from the amino acid tryptophan, and contain an ETP ring fused to a 
cyclotryptamine. 4    
 Kishi’s total synthesis of fungal metabolite gliotoxin (2.1) is a milestone in the 
synthetic efforts towards natural products containing ETPs (Figure 2.1).5 Sporidesmin A 
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Figure 2.1. Some structurally and functionally important epithiodiketopiperazines 
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(2.2),6 cytotoxic, dimeric ETP (+)-11,11'-dideoxyverticillin A (2.3),7 and dimeric (+)-
chaetocin (2.4),8 are among the ETP natural products that have been synthesized. 
Cytotoxic T988 A (2.5),9 chaetomin (2.6), and chaetocochins C (2.7),10 are among the 
ETP natural products that have not been synthesized.  
 Chaetomin was first isolated by Waksman and Bugie11 from a strain of 
Chaetomium cochliodes, and was found to possess antibiotic activity12 and 
immunomodulatory activity.13 Recently, chaetomin spurred interest among scientists by 
exhibiting anti cancer activity by inhibiting the hypoxia inducible factor 1 α (HIF-1 α), 
binding to the target protein p300/CBP.14   As hypoxia enhances radioresistance in tumors 
and mediates resistance to chemotherapy, it was found that chaetomin influences the 
radiosensitivity of hypoxic  cells in vitro.15      
 Hypoxia, the state of reduced oxygen levels, is characteristic of tumors. 
Adaptations to hypoxic conditions are mediated by a transcription factor HIF-1; thus 
HIF-1 has become an attractive target in anticancer therapy. HIF-1 is a heterodimeric 
protein comprising of HIF-1α and HIF-1 ß subunits. HIF-1 α degrades rapidly under 
normoxic conditions and stabilizes under hypoxic conditions.16 Under hypoxic 
conditions, the HIF-1 α subunit binds to the transcriptional coactivator p300/CBP; it 
subsequently dimerizes by binding to the HIF-1 ß subunit. Thereby, the dimer activates 
the hypoxia-inducible genes, such as genes that control angiogenesis, energy metabolism, 
and erythropoiesis.17 Chaetomin disrupts the structure of the p300 and precludes its 
interaction with HIF-1 α, thereby interfering with the survival of tumors under hypoxic 
conditions. Thus, chaetomin’s conspicuous biological role and its intricate heterodimeric 
architecture have made it an attractive synthetic target. 
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                                                                Background       
 The highly reactive disulfide bridge is one of the major challenges in the synthesis 
of epidithiodiketopiperazine natural products. The first synthesis of an ETP moiety was 
reported by Trown in 1968 (Scheme 2.1).18 Bromination of the sarcosine anhydride 
afforded the 3,6-dibromide 2.8 in 70% yield. Nucleophilic displacement of bromine with 
potassium thioacetate afforded the 3,6-dithioacetate 2.9 in 95% yield. Hydrolysis of 2.9 
in ethanolic HCl provided the dimercaptan 2.10, subsequent oxidation with Ellman's 
reagent gave the disulfide 2.11 in 72% yield. Disulfide 2.11 exhibited antiviral activity 
and desulfurization resulted in a loss of biological activity, which signifies the fact that 
the active center of these ETP natural products is the epidithiapiperazinedione moiety.  
 Inspired by the chaetocin’s (2.4) and chaetomin’s (2.6) biological activity, Block et 
al. designed a small molecule, dimeric ETP, which is an inhibitor of the hypoxia-
inducible transcription factor complex.19 They observed disulfide dimer 2.12 to have 
significant activity compared to the control 2.13, which lacks the disulfide bridge (Figure 
2.2). This loss of activity in 2.13 further emphasizes the importance of ETP moiety for 
the biological role.            
 The highly labile nature of the disulfide bridge under reductive, basic, and acidic 
conditions is a major concern in the total synthesis of ETP natural products. Therefore, 
Kishi and coworkers, in their synthesis of ETP natural products, protected the dithiol 2.10 
as the p-anisaldehydedithioacetal 2.14, by reaction with p-anisaldehyde and BF3.OEt2 
(Scheme 2.2). The thioacetal is stable under acidic, basic or reductive conditions and can 
be smoothly cleaved to the disulfide 2.11 with m-CPBA and acid (such as BF3.OEt2, 
BC13, H2SO4 or HClO4).  
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                                    Scheme 2.2. Kishi’s synthesis of dithioacetal   
 
  Interestingly, Kishi and coworkers observed an acidity difference in the 
bridgehead protons Ha and Hb, which enables them to regiospecifically functionalize the 
bridgehead positions. The bridgehead carbanion was generated using alkyllithium 
reagents, which was immediately quenched with an alkylating or acylating agent.20  
  The indole-diketopiperazine bridge is an important structural feature of the 
northern hemisphere of chaetomin 2.6. Several attempts have been reported in the 
literature on alkylation of DKP with an indole moiety. For instance, in the total synthesis 
of sporidesmin A,6 bridgehead carbanion of 2.15 was generated using butyllithium, which 
was then acylated with indole acyl chloride 2.16 to give 2.17 (Scheme 2.3). Furthermore, 
Kametani and Somei reported coupling of gramine 2.18 with the nucleophilic DKP 
substrate 2.19 in the presence of trialkylphosphine to give 2.20 in 42% yield (Scheme 
2.4). During the course of our synthesis, Dubey and Olenyuk reported their attempts to 
improve the efficiency and yields of the above reaction and were able to obtain higher 
yields by replacing trialkylphosphine with quinine.21 Outlined here in the second chapter 
of this thesis are studies directed towards the synthesis of indole-diketopiperazines.  
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                                                                      Reterosynthesis 
A convergent reterosynthetic approach towards chaetomin is proposed here 
(Scheme 2.5). It was envisioned that chaetomin 2.6 would arise from the final disulfide 
bridge installation in 2.21. The chaetomin precursor 2.21 would come from the coupling 
of advanced intermediates 2.22 and 2.23, using the C(3)-N(1’) heterodimeric indoline 
synthesis strategy developed by our group.22 The 2.22 would arise from the alkylation of 
the skatole derivative 2.24 with DKP 2.25 and subsequent primary alcohol installation. 
The DKP synthesis between tryptophan and serine and the subsequent bromocyclization 
would provide the bromopyrroloindoline 2.23. 
 
                                             Results and Discussion           
 Initially, we synthesized diketopiperazine derivative 2.14 from sarcosine 
anhydride (Scheme 2.6).18,20 Sarcosine anhydride was reacted with NBS to give the 
corresponding dibrominated product, which on reaction with KSAc provided the 
dithioacetate product 2.9. Subsequent hydrolysis of the acetate ester in acidic MeOH 
provided the dithiol compound, which was protected with p-anisaldehyde in BF3.OEt2, to 
give p-anisaldehydedithioacetal 2.14 in 40-45% yield over four steps. With 2.14 in hand, 
the next step was to investigate the coupling of 2.14 with the indole moiety.    
Towards this endeavor, tosylation of skatole provided 2.26, which was 
brominated in the presence of NBS and Bz2O2 to give 2.27 (Scheme 2.7).23 In order to 
form the indole-diketopiperazine bridge, the bridgehead carbanion of 2.14 was generated 
with LHMDS in THF at -78 oC (Scheme 2.8). Subsequent quenching of the carbanion 
with 2.27 provided the alkylated ETP product 2.28 in 25% yield with isolated 2.14.  
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Scheme 2.5. Reterosynthesis of chaetomin 
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Scheme 2.8. Synthesis of indole-diketopiperazine bridge 
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The tosyl group in 2.28 needed to be deprotected prior to the C(3)-N(1’) 
heterodimeric coupling with bromopyrroloindoline 2.23. Although the tosyl group is 
known to be cleaved under much harsher reductive conditions, we were much concerned 
about the sensitivity of thioacetal in 2.28 under these harsher conditions. There are 
several reports of the removal of the tosyl group under milder conditions, such as in 
KOH/ H2O/ THF,24a and Cs2CO3/ MeOH/ THF.24b Attempts to deprotect the tosyl group 
in 2.28 using KOH, NaOH, and NaH in MeOH proved to be fruitless, resulting in 
recovery of starting material. Meanwhile, in trying to optimize the conditions for the 
detosylation, we intended for the synthesis of the brominated skatole with a different 
protecting group, which could be cleaved under much milder conditions.  
Thus our first choice was to have a nosyl group instead of tosyl, so that it could be 
cleaved under much milder conditions, such as K2CO3, Cs2CO3 or PhSH. However, 
following the same procedure as in 2.27, attempts to brominate nosylated skatole to give 
2.29 were not very successful (Figure 2.3). Therefore, we decided to protect skatole with 
a Boc group, planning on cleaving it with TFA at a later stage. It is reported that the DKP 
thioacetals are usually stable to acidic conditions.20 This stability was proved again when 
we stirred 2.28 in TFA overnight, wherein we were able to still isolate the 2.28 
unaffected. Thus we synthesized Boc protected brominated skatole 2.30,25 and focused on 
subsequent alkylation with thioacetal protected DKP 2.14. It should be noted that care 
should be involved in handling these brominated skatole moieties. They are highly 
unstable, and in a matter of hours at RT lead to a debromo product, which cannot induce 
the subsequent alkylation reaction. 
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                             Figure 2.3. Brominated skatole derivatives   
            
     Conclusion	          
 To our knowledge, the above method provides a rapid and convergent entry into 
the northern hemisphere of chaetomin. However, more work needs to be done to optimize 
the alkylation reaction to gain higher yields, and to find suitable conditions for 
detosylation. Studies aimed at accomplishing these goals are underway. 
 
                                                  Experimental Section   
 THF was distilled from sodium and benzophenone. All other reagents were used 
without further purification unless otherwise stated. Glassware for the reactions was oven 
dried or flame dried and cooled prior to use. All reactions were run under an atmosphere 
of nitrogen or argon unless otherwise stated. Yields were calculated for material judged 
homogenous by thin layer chromatography and NMR.  Thin layer chromatography was 
performed on Silica gel 60 F254 plates eluting with the solvent indicated, visualized by a 
254/ 365 nm UV lamp, and stained with solutions of p-anisaldehyde, potassium 
permanganate or iodine chamber. Column chromatography was performed with 40–63 
µm silica gel. NMR spectra were acquired on the i400 spectrometer. Chemical shifts for 
1H NMR spectra are reported in parts per million relative to the signal of residual CHCl3 
at 7.27 ppm. Chemicals shifts for 13C NMR spectra are reported in parts per million 
	   	   	   65    	  
	  
relative to the center line of the CDCl3 triplet at 77.23 ppm. The abbreviations s, d and m 
stand for the resonance multiplicity singlet, doublet and multiplet, respectively. IR 
spectra were obtained from Nicolet 380 FT-IR spectrometer. Mass spectra were recorded 
at the Mass Spectrometry facility in the Department of Chemistry of the University of 
Utah.             
    
               Reaction procedure and characterization of the product 
Synthesis of indole DKP bridge 2.28. To a 
solution of 2.14 (0.046 g, 0.142 mmol) in THF (4 ml) at -78 oC, LHMDS (0.17 ml,      
0.17 mmol) was added and stirred for 1.5 min. A solution of 2.27 (0.1 g, 0.274 mmol) in 
THF (2 ml) was added for 2 min. The mixture was stirred at -78 oC for 0.5 h and slowly 
warmed to RT. After stirring at RT for 1 h, the reaction was quenched with saturated 
NaCl and extracted the aqueous phase with CH2Cl2 (3 x 25 ml). The combined organic 
extracts were washed with brine, dried (Na2SO4) and concentrated. The crude material 
was purified by silica flash column chromatography (4:6 EtOAC: Hexane) to afford 
0.021 g (25%) of 2.28 as a yellowish oil. (Rf = 0.45 in 4:6 EtOAC: Hexane). 
 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 8.4 Hz, 1 H), 7.62 (d, J = 8.4 Hz, 2 H), 
7.44 (d, J = 8.4 Hz, 1 H), 7.33 (d, J = 8.8 Hz, 2 H), 7.29 (d, J = 8.4 Hz, 1 H), 7.25- 7.21 
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(m, 2 H), 7.17 (d, J = 6.8 Hz, 2 H), 6.85 (d, J = 8.8 Hz, 2 H), 5.22 (s, 1 H), 5.09 (s, 1 H), 
3.91 (d, J = 16.5 Hz, 1 H), 3.79 (s, 3 H), 3.21 (d, J = 16.5 Hz, 1 H), 3.16 (s, 3 H), 2.98 (s, 
3 H), 2.31 (s, 3 H). 13C NMR (100 MHz, CDCl3) δ 165.7, 164.6, 160.9, 145.2, 135.1, 
134.9, 130.9, 130.7, 130.1, 126.9, 126.7, 125.4, 124, 123.7, 118.9, 116.4, 114.6, 114.2, 
71.2, 66.3, 55.6, 50.9, 31.1, 30.6, 28.1, 21.8. IR (neat): 2922 cm-1, 2852   cm-1, 1685 cm-1, 
1173 cm-1. LRMS (ESI) m/z calc’d for C30H29N3O5S3 (MNa+): 630.1, (MK+): 646.1; 
found (MNa+): 630.1, (MK+): 646.1. 
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